Research Article

Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor

Volume: 13 Number: 4 December 15, 2023
EN TR

Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor

Abstract

Natural products have historically made a significant contribution to pharmacotherapy, especially for cancer diseases. Garlic contains a variety of bioactive molecules with anticancer effects, including allicin and diallyl disulfide. In this study, optimization computations were performed in the Gaussian 09 W utilizing the DFT with functional B3LYP method/6-31++G(d,p) basis set for allicin and diallyl disulfide. Drug-likeness and ADME-Tox properties were examined. Molecular docking was achieved to research the biological knowledge of allicin and diallyl disulfide. The protein preferred in these computations is the crystal structure of the 5XGN, EGFR mutants T790M/C797S complex. The binding energies for the allicin and diallyl disulfide molecules-EGFR mutants T790M/C797S complex were computed as -8.3 kcal/mol and -8.2 kcal/mol respectively. Meaningful results were achieved for these two compounds.

Keywords

Allicin, Diallyl disulfide, DFT, HOMO-LUMO, Molecular docking, Garlic

References

  1. Akan, S. (2014). Health Promoting Properties of Garlic (Allium sativum L.) Consumption. Akademik Gıda, 12(2), 95-100.
  2. Ali Abdalla, Y. O., Subramaniam, B., Nyamathulla, S., Shamsuddin, N., Arshad, N. M., Mun, K. S., Awang, K., Nagoor, N. H. (2022). Natural products for cancer therapy: a review of their mechanism of actions and toxicity in the past decade. Journal of Tropical Medicine, 2022.
  3. Bailly, C. (2019). Irinotecan: 25 years of cancer treatment. Pharmacological research, 148, 104398.
  4. Baldwin, E. L., and Osheroff, N. (2005). Etoposide, topoisomerase II and cancer. Current Medicinal Chemistry-Anti-Cancer Agents, 5(4), 363-372.
  5. Banerjee, P., and Ulker, O. C. (2022). Combinative ex vivo studies and in silico models ProTox-II for investigating the toxicity of chemicals used mainly in cosmetic products. Toxicology mechanisms and methods, 32(7), 542-548.
  6. Bayoumy, A. M., Ibrahim, M., Omar, A. (2020). Mapping molecular electrostatic potential (MESP) for fulleropyrrolidine and its derivatives. Optical and Quantum Electronics, 52, 1-13.
  7. Bazaraliyeva, A., Moldashov, D., Turgumbayeva, A., Kartbayeva, E., Kalykova, A., Sarsenova, L., & Issayeva, R. (2022). Chemical and biological properties of bio-active compounds from garlic (Allium sativum). Pharmacia, 69(4), 955-964.
  8. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
  9. Bulat, F. A., Toro-Labbé, A., Brinck, T., Murray, J. S., Politzer, P. (2010). Quantitative analysis of molecular surfaces: areas, volumes, electrostatic potentials and average local ionization energies. Journal of molecular modeling, 16, 1679-1691.
  10. Butt, S. S., Badshah, Y., Shabbir, M., Rafiq, M. (2020). Molecular docking using chimera and autodock vina software for nonbioinformaticians. JMIR Bioinformatics and Biotechnology, 1(1), e14232.
APA
Çağlar Yavuz, S. (2023). Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor. Karadeniz Fen Bilimleri Dergisi, 13(4), 1523-1539. https://doi.org/10.31466/kfbd.1307190
AMA
1.Çağlar Yavuz S. Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor. KFBD. 2023;13(4):1523-1539. doi:10.31466/kfbd.1307190
Chicago
Çağlar Yavuz, Sevtap. 2023. “Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor”. Karadeniz Fen Bilimleri Dergisi 13 (4): 1523-39. https://doi.org/10.31466/kfbd.1307190.
EndNote
Çağlar Yavuz S (December 1, 2023) Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor. Karadeniz Fen Bilimleri Dergisi 13 4 1523–1539.
IEEE
[1]S. Çağlar Yavuz, “Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor”, KFBD, vol. 13, no. 4, pp. 1523–1539, Dec. 2023, doi: 10.31466/kfbd.1307190.
ISNAD
Çağlar Yavuz, Sevtap. “Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor”. Karadeniz Fen Bilimleri Dergisi 13/4 (December 1, 2023): 1523-1539. https://doi.org/10.31466/kfbd.1307190.
JAMA
1.Çağlar Yavuz S. Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor. KFBD. 2023;13:1523–1539.
MLA
Çağlar Yavuz, Sevtap. “Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor”. Karadeniz Fen Bilimleri Dergisi, vol. 13, no. 4, Dec. 2023, pp. 1523-39, doi:10.31466/kfbd.1307190.
Vancouver
1.Sevtap Çağlar Yavuz. Molecular Docking and Reactive Sites Identification (Homo–Lumo, Mep) of Allicin and Diallyl Disulfide: Potential Anticancer Inhibitor. KFBD. 2023 Dec. 1;13(4):1523-39. doi:10.31466/kfbd.1307190